ADC Therapeutics' Revenue Growth Outlook Remains Unclear, RBC Capital Markets Says

MT Newswires Live11-11

ADC Therapeutics' (ADCT) recent restructuring improved the company's financial position and its Lotis-7 data looked encouraging, but outlook for revenue growth remains unclear given the competitive landscape in diffuse large B-cell lymphoma, RBC Capital Markets said in a note Monday.

The company reported Q3 revenue at the high end of Zynlonta's historical range, as previously announced, while maintaining good control over expenses, the investment firm said.

The company has a potential path forward, but the Lotis-7 data remains immature, RBC said, adding that additional data from subgroups could help contextualize the drug in the "highly competitive" DLBCL landscape.

RBC Capital Markets has a sector perform, speculative risk rating on ADC Therapeutics, with a $2 price target.

Shares of ADC Therapeutics were down 9.6% in Tuesday trading.

Price: 1.51, Change: -0.16, Percent Change: -9.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment